重组治疗性蛋白质的配方:技术创新,法规和向没有缓冲区的配方的发展
1Escuela de Ciencias Empresariales, Universidad Católica del Norte, Coquimbo 1780000, Chile.
Pharmaceutics
|September 27, 2025
概括
治疗蛋白质的无缓冲器配方正在获得引力,增强稳定性和患者体验. 这种转变简化了生产,并与生物制剂的监管趋势保持一致.
科学领域:
- 生物制药的发展.
- 蛋白质配方科学 蛋白质配方科学
背景情况:
- 治疗性蛋白质配方对于安全性,有效性和稳定性至关重要.
- 没有缓冲剂的配方正在出现,以减少免疫性和生产复杂性.
研究的目的:
- 审查技术进步,监管前景以及无缓冲区蛋白质配方的安全性.
- 探索生物制药中向最小化配方的转变.
主要方法:
- 使用PSALSAR框架进行系统性文档审查.
- 分析科学出版物,专利和监管文件 (2020-2025年).
- 专注于重组蛋白,没有缓冲区的配方和监管调整.
主要成果:
- 越来越多地采用皮下生物药物的自缓冲策略.
- 像Fc-fusion,PASylation和XTENylation这样的技术可以在没有常规缓冲器的情况下提高稳定性.
- 监管机构 (FDA,EMA) 越来越多地接受具有安全性和生物相似性的简约配方.
结论:
- 没有缓冲区的配方为治疗性蛋白质开发提供了一个有希望的替代方案.
- 这些配方改善了患者体验,减少了复杂性,与生物类似目标保持一致.
- 长期的透明度和安全评估对于广泛采用至关重要.
关键词:
美国FDA/EMA监管框架这就是IP IP IP IP.生物类似配方的生物类似配方缓冲剂的配方 缓冲剂的配方没有缓冲区的配方.助剂的安全性 助剂的安全性免疫性 免疫性 免疫性知识产权知识产权是知识产权.药品创新 药品创新 药品创新 药品创新蛋白质配方 皮下生物制品重组治疗性蛋白质的重组治疗性蛋白质更多相关视频
06:24Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
Published on: December 15, 2017
10.6K
10:50Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
Published on: May 1, 2019
15.2K
相关概念视频
Recombinant DNA
101.7K
Overview
101.7K
Biopharmaceutical Factors Influencing Drug Product Design: Overview
233
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
233
Drug Products: Biologics, Biosimilars and Interchangeables
235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
151
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
151
